These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10987352)

  • 41. Long-term effects of benazepril on ambulatory blood pressure, left ventricular mass, diastolic filling and aortic flow in essential hypertension.
    Porcellati C; Verdecchia P; Schillaci G; Boldrini F; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1991 May; 29(5):187-97. PubMed ID: 1830037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study.
    Dahlöf B; Gosse P; Guéret P; Dubourg O; de Simone G; Schmieder R; Karpov Y; García-Puig J; Matos L; De Leeuw PW; Degaute JP; Magometschnigg D;
    J Hypertens; 2005 Nov; 23(11):2063-70. PubMed ID: 16208150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of drug therapy on hypertensive left ventricular hypertrophy.
    Fletcher PJ; Horvath JS; Bailey BP; Tiller D
    Clin Exp Pharmacol Physiol; 1985; 12(3):291-4. PubMed ID: 3161673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis.
    Imanaka K; Kohmoto O; Nishimura S; Yokote Y; Kyo S
    Eur J Cardiothorac Surg; 2005 Jun; 27(6):994-9. PubMed ID: 15896607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism.
    Indra T; Holaj R; Štrauch B; Rosa J; Petrák O; Šomlóová Z; Widimský J
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1109-17. PubMed ID: 25271250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation.
    Mancia G; Zanchetti A; Agabiti-Rosei E; Benemio G; De Cesaris R; Fogari R; Pessina A; Porcellati C; Rappelli A; Salvetti A; Trimarco B
    Circulation; 1997 Mar; 95(6):1464-70. PubMed ID: 9118514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients.
    Manolis AJ; Kolovou G; Handanis S; Athanasopoulos G; Antonopoulos S; Cokkinos DV
    Am J Hypertens; 1993 Mar; 6(3 Pt 2):86S-88S. PubMed ID: 8466737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study.
    Papademetriou V; Devereux RB; Narayan P; Wachtell K; Bella JN; Gerdts E; Chrysant SG; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):768-74. PubMed ID: 11497192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of left-ventricular mass and its response to antihypertensive treatment.
    Rowlands DB; Glover DR; Ireland MA; McLeay RA; Stallard TJ; Watson RD; Littler WA
    Lancet; 1982 Feb; 1(8270):467-70. PubMed ID: 6121138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension.
    Tsioufis C; Stougiannos P; Kakkavas A; Toutouza M; Mariolis A; Vlasseros I; Stefanadis C; Kallikazaros I
    Am J Cardiol; 2005 Jul; 96(2):252-6. PubMed ID: 16018852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension.
    El-Gharbawy AH; Nadig VS; Kotchen JM; Grim CE; Sagar KB; Kaldunski M; Hamet P; Pausova Z; Gaudet D; Gossard F; Kotchen TA
    Hypertension; 2001 Mar; 37(3):845-50. PubMed ID: 11244006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension].
    Bignotti M; Lamponi M
    Minerva Cardioangiol; 1996 Jun; 44(6):331-5. PubMed ID: 8927264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Correlations between blood pressure, left ventricular hypertrophy, and left ventricular diastolic function in hypertensive patients].
    Ito O; Okamoto M; Murakami Y; Nakayama R
    J Cardiol; 1991; 21(4):931-41. PubMed ID: 1844449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood pressure determinants of left ventricular wall thickness and mass index in hypertension: comparing office, ambulatory and exercise blood pressures.
    Lim PO; Donnan PT; MacDonald TM
    J Hum Hypertens; 2001 Sep; 15(9):627-33. PubMed ID: 11550109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Left ventricular mass change during treatment and outcome in patients with essential hypertension.
    Koren MJ; Ulin RJ; Koren AT; Laragh JH; Devereux RB
    Am J Hypertens; 2002 Dec; 15(12):1021-8. PubMed ID: 12460696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
    Bella JN; Palmieri V; Wachtell K; Liu JE; Gerdts E; Nieminen MS; Koren MJ; Zabalgoitia M; Wright JT; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):411-6. PubMed ID: 15042116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
    Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
    Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.